Newsroom

News and developments from Affinia Therapeutics

For media inquiries: media@affiniatx.com.

  • All
  • Press Releases
  • Publications
  • Presentations

Press Release – September 8, 2021

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group

Read More

Press Release – July 20, 2021

Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) To Rationally Design Novel CNS Promoters for Gene Therapy

Read More

Presentation – May 13, 2021

AAVX Resin Binding Site Identification Via Library Screening Analysis on Novel AAV Vectors

Read More

Presentation – May 11, 2021

AAVmod2, an AAV Capsid Engineered to Independently Detarget the Liver and Enhance Gene Delivery to Skeletal Muscle

Read More

Presentation – May 11, 2021

CSF delivery of Anc80L65 in the non-human primate brain results in widespread gene transfer throughout the central nervous system compared to AAV9

Read More

Presentation – May 11, 2021

Network Analysis of Complex Novel AAV Vector Library Datasets for De-risking Gene Therapy Candidate Selection

Read More

Press Release – May 13, 2021

Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting

Read More

Press Release – May 3, 2021

Affinia Therapeutics Closes $110 Million Series B Financing

Read More

Press Release – April 27, 2021

Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting

Read More

Press Release – February 17, 2021

Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic

Read More

Press Release – June 8, 2020

Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors

Read More

Press Release – April 27 2020

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

Read More

Press Release – March 31, 2020

Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies

Read More

Publication – Jul 8, 2019

Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans

Read More

Publication – Jul 23, 2018

Efficient gene transfer to the central nervous system by single-stranded Anc80L65

Read More

Publication – Aug 11, 2015

In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector

Read More